Zentalis Pharmaceuticals announced that its management team will participate in two investor conferences in November 2026: Guggenheim's Healthcare Innovation Conference on November 10 and Stifel Healthcare Conference on November 11. The company is advancing late-stage development of its investigational WEE1 inhibitor, azenosertib, targeting ovarian cancer. These presentations aim to update investors on clinical progress and strategic plans. Webcasts of the events will be available on Zentalis' website for broader access.
Zentalis Pharmaceuticals is noted here with Pluang's health sector market context as of Nov 04, 2026 04:11 WIB: Among 150 priced health-sector US stocks tradable on Pluang, 92 advanced and 55 declined today. Key movers included Iovance Biotherapeutics Inc. (IOVA) with a 10.47% gain and 99% sell order activity, Ginkgo Bioworks Holdings Inc. (DNA) up 9.04% with 67% sell orders, and AbCellera Biologics Inc. (ABCL) rising 8.90% with 100% buy orders and a typical hold time of 42 days.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
Postal Realty Trust, Inc. announced a net income of $0.16 per diluted share for Q3 2026, driven by acquisitions of 145 USPS properties worth $82 million and a 25.2% increase in rental income year-over-year. The company raised its 2026 acquisition gui...
Crescent Biopharma awarded stock options for 11,775 shares to a new non-executive employee as part of an inducement plan approved by its Compensation Committee. The options have a 10-year term with an exercise price of $12.91, matching the closing sh...
HP Inc. will announce its financial results for the fourth quarter and full fiscal year ending October 31, 2026, on November 24, 2026, via a live webcast. The company will also participate in several investor conferences in December, including UBS Gl...
